| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/1744666X.4.3.365 |
| P8608 | Fatcat ID | release_uluiolzc25dfjjlyjr5gr45e7a |
| P698 | PubMed publication ID | 20476926 |
| P2093 | author name string | Don D Sin | |
| Sf Paul Man | |||
| Tammy Sy Mui | |||
| P2860 | cites work | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease | Q22299313 |
| Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study | Q28239287 | ||
| Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; two case reports | Q28255739 | ||
| Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease | Q28261960 | ||
| Oxidative Stress in Chronic Obstructive Pulmonary Disease | Q28747125 | ||
| Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases | Q29547555 | ||
| Chemokines--chemotactic cytokines that mediate inflammation | Q29616433 | ||
| Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients | Q30039680 | ||
| Perforin-independent CD8(+) T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-alpha: relative insensitivity to Fas ligand | Q30303947 | ||
| Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review. | Q30872006 | ||
| Matrix metalloproteinases. Matrix degradation and more | Q33643000 | ||
| Neutrophils and protease/antiprotease imbalance | Q33771459 | ||
| Inhibition of p38 MAP kinase as a therapeutic strategy | Q33957191 | ||
| Pharmacology of bronchodilators used in the treatment of COPD. | Q34042393 | ||
| ONO-5046, a novel inhibitor of human neutrophil elastase | Q34116783 | ||
| Anti-TNF-alpha therapies: the next generation | Q34227176 | ||
| Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells | Q34244537 | ||
| Airway inflammation and tachykinins: prospects for the development of tachykinin receptor antagonists | Q34430683 | ||
| Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD | Q34542927 | ||
| Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial | Q34557270 | ||
| The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials | Q34727099 | ||
| Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells | Q34731017 | ||
| Anticholinergics in the treatment of chronic obstructive pulmonary disease | Q34778358 | ||
| Chronic obstructive pulmonary disease . 7: Management of COPD | Q35075588 | ||
| Interleukin-10 therapy--review of a new approach | Q35139563 | ||
| Exhaled leukotrienes and prostaglandins in COPD. | Q35536034 | ||
| Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis | Q35536791 | ||
| Contemporary management of chronic obstructive pulmonary disease: scientific review | Q35576640 | ||
| Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. | Q35682823 | ||
| IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes | Q35766246 | ||
| Therapeutic responses in asthma and COPD. Corticosteroids | Q35859733 | ||
| Accelerated atherosclerosis in inflammatory rheumatic diseases | Q35932689 | ||
| Perspectives for cytokine antagonist therapy in COPD. | Q36046543 | ||
| Drugs in clinical development for chronic obstructive pulmonary disease | Q36064621 | ||
| Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD | Q36169173 | ||
| Value of theophylline treatment in patients handicapped by chronic obstructive lung disease | Q36276399 | ||
| Emerging drugs for the treatment of chronic obstructive pulmonary disease | Q36458412 | ||
| TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease | Q36828400 | ||
| Pharmacologic therapy: novel approaches for chronic obstructive pulmonary disease | Q36945372 | ||
| Muscarinic receptor subtypes in airways | Q39583662 | ||
| Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist | Q40134007 | ||
| A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation | Q40134015 | ||
| Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration | Q40580109 | ||
| The interrelationship of sputum inflammatory markers in patients with chronic bronchitis | Q40798956 | ||
| Metalloproteinase inhibitors and the prevention of connective tissue breakdown | Q40956886 | ||
| Potential role of recombinant secretory leucoprotease inhibitor in the prevention of neutrophil mediated matrix degradation | Q41232199 | ||
| COPD: overview of definitions, epidemiology, and factors influencing its development | Q41743654 | ||
| Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. | Q42117582 | ||
| MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial | Q42553610 | ||
| Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease | Q43732336 | ||
| A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. | Q44061866 | ||
| The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease | Q44550733 | ||
| A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice | Q44586798 | ||
| Cigarette smoke alters chromatin remodeling and induces proinflammatory genes in rat lungs | Q45033935 | ||
| Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial | Q46649423 | ||
| First study of infliximab treatment in patients with chronic obstructive pulmonary disease | Q47785823 | ||
| Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. | Q47988631 | ||
| Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease | Q48016346 | ||
| Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. | Q51108291 | ||
| Persistence of the effect of the Lung Health Study (LHS) smoking intervention over eleven years. | Q51696244 | ||
| Smoking and lung function of Lung Health Study participants after 11 years. | Q51705571 | ||
| A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. | Q51761993 | ||
| A 46-year-old female with dyspnoea, stridor and chronic cough. | Q51788118 | ||
| Decreased histone deacetylase activity in chronic obstructive pulmonary disease. | Q54664094 | ||
| Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. | Q55042765 | ||
| A Calcium-Activated Chloride Channel Blocker Inhibits Goblet Cell Metaplasia and Mucus Overproduction | Q56601543 | ||
| Estimates of global mortality attributable to smoking in 2000 | Q57074345 | ||
| Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease | Q58877159 | ||
| P433 | issue | 3 | |
| P921 | main subject | chronic obstructive pulmonary disease | Q199804 |
| P304 | page(s) | 365-377 | |
| P577 | publication date | 2008-05-01 | |
| P1433 | published in | Expert Review of Clinical Immunology | Q15733763 |
| P1476 | title | Developments in drugs for the treatment of chronic obstructive pulmonary disease | |
| P478 | volume | 4 |
Search more.